review
inform
use
laboratori
test
screen
diagnosi
monitor
acut
chronic
hepat
injuri
data
sourc
studi
select
medlin
search
perform
key
word
relat
hepat
diseas
includ
acut
hepat
chronic
hepat
alcohol
hepat
cirrhosi
hepatocellular
carcinoma
etiolog
caus
abstract
review
articl
discuss
use
laboratori
test
select
review
addit
articl
select
refer
guidelin
prepar
review
draft
guidelin
post
internet
present
aacc
annual
meet
review
expert
area
requir
amplif
literatur
review
identifi
analysi
specif
recommend
made
base
analysi
publish
data
evalu
strength
evid
clinic
impact
recommend
although
mani
specif
recommend
made
guidelin
summari
recommend
list
acut
hepat
injuri
prothrombin
time
lesser
extent
total
bilirubin
best
indic
sever
diseas
although
alt
use
detect
acut
chronic
hepat
injuri
relat
sever
acut
hepat
injuri
weakli
relat
sever
chronic
hepat
injuri
specif
test
viral
marker
initi
differenti
test
acut
chronic
hepat
injuri
posit
also
use
monitor
recoveri
hepat
b
c
death
liver
diseas
western
countri
chronic
liver
diseas
among
common
disord
seen
physician
present
guidelin
use
laboratori
test
screen
diagnosi
monitor
acut
chronic
hepat
injuri
acut
hepat
injuri
recogn
presenc
jaundic
nonspecif
symptom
acut
ill
accompani
increas
activ
aspart
aminotransferas
ast
ec
andor
alanin
aminotransferas
alt
ec
estim
individu
acut
viral
hepat
never
diagnos
clinic
although
may
detect
increas
aminotransferas
face
nonspecif
absent
clinic
symptom
ast
alt
activ
seldom
time
upper
refer
limit
liver
diseas
acut
hepat
injuri
alkalin
phosphatas
alp
ec
three
time
upper
refer
limit
case
acut
hepat
injuri
decreas
incid
acut
viral
hepat
liver
diseas
commonli
encount
caus
increas
ast
alt
activ
mani
ast
time
refer
limit
may
obstruct
caus
approxim
patient
bile
duct
obstruct
transient
increas
ast
andor
alt
activ
ul
aminotransferas
activ
usual
fall
within
refer
limit
day
even
obstruct
persist
distribut
direct
bilirubin
percentag
total
bilirubin
similar
acut
hepat
injuri
obstruct
jaundic
patient
jaundic
acut
hepat
injuri
direct
bilirubin
total
bilirubin
valu
suggest
anoth
caus
jaundic
hemolysi
best
discrimin
valu
recogn
acut
hepat
injuri
appear
ul
ast
sensit
specif
ul
alt
sensit
specif
ast
time
upper
refer
limit
slightli
onehalf
patient
time
present
uncompl
alcohol
hepat
ast
alt
valu
almost
never
time
upper
refer
limit
astalt
ratio
case
increas
alp
present
case
jaundic
occur
case
alcohol
hepat
frequenc
jaundic
patient
acut
viral
hepat
differ
age
etiolog
agent
jaundic
rare
children
viral
hepat
present
less
sever
adult
one
studi
children
acut
hepat
peak
bilirubin
moll
mgdl
wherea
adult
adult
jaundic
develop
case
acut
hepat
case
acut
hepat
b
case
acut
hepat
c
children
direct
correl
age
peak
serum
bilirubin
increas
year
age
associ
averag
increas
moll
mgdl
bilirubin
adult
howev
slight
increas
increas
increas
age
acut
hepat
injuri
diagnos
alt
time
upper
refer
limit
alp
time
appropri
upper
refer
limit
iib
acut
viral
hepat
b
usual
selflimit
ill
patient
recov
complet
acut
hepat
c
infect
develop
chronic
hepat
rare
acut
hepat
injuri
caus
sever
liver
damag
acut
liver
failur
test
identifi
patient
highest
risk
liver
failur
aminotransferas
activ
relat
caus
hepat
injuri
sever
tabl
weak
correl
aminotransferas
activ
bilirubin
viral
hepat
none
ischem
hepat
injuri
peak
aminotransferas
activ
bear
relationship
prognosi
may
fall
worsen
patient
condit
prothrombin
time
pt
import
predictor
prognosi
pt
cutoff
time
beyond
control
intern
normal
ratio
identifi
patient
high
risk
death
alcohol
hepat
pt
beyond
control
bilirubin
moll
mgdl
albumin
gl
gdl
patient
year
age
predict
likelihood
death
ischem
toxic
hepat
injuri
prolong
pt
common
earli
injuri
valu
peak
h
injuri
rapidli
return
normal
acetaminophen
injuri
mark
prolong
pt
indic
likelihood
liver
failur
persist
increas
increas
pt
day
acetaminophen
ingest
peak
bilirubin
good
indic
prognosi
form
hepat
injuri
total
bilirubin
moll
mgdl
pt
upper
refer
limit
clinic
chemistri
indic
sever
liver
injuri
mandat
close
monitor
encephalopathi
total
bilirubin
moll
mgdl
pt
upper
refer
limit
individu
viral
hepat
absenc
factor
affect
result
indic
sever
liver
injuri
iib
direct
bilirubin
need
rule
caus
increas
total
bilirubin
hemolysi
differenti
hepat
injuri
obstruct
jaundic
iib
acetaminophen
toxic
persist
increas
increas
pt
day
ingest
indic
sever
liver
injuri
iib
initi
laboratori
evalu
patient
acut
hepat
injuri
includ
drug
histori
test
antibodi
hepat
b
c
virus
hav
hbv
hcv
use
health
care
financ
administrationapprov
acut
hepat
panel
igm
hav
igm
antihav
hbv
core
antigen
igm
antihbc
hbv
surfac
antigen
hbsag
antibodi
hcv
antihcv
fig
hepat
drug
reaction
occur
within
month
initi
treatment
howev
case
hepat
injuri
may
becom
manifest
late
month
treatment
initi
case
injuri
may
becom
evid
day
week
respons
drug
stop
henc
import
ask
drug
patient
may
receiv
continu
receiv
past
year
igm
antihav
diagnost
test
choic
acut
hav
infect
disappear
month
wherea
total
hav
antibodi
persist
life
found
high
percentag
popul
brief
period
transmiss
diagnosi
acut
hav
infect
made
soon
possibl
present
ideal
within
h
allow
immun
globulin
treatment
expos
individu
igm
antihbc
hbsag
reliabl
test
acut
hbv
infect
igg
thu
total
antihbc
persist
mani
year
hbv
viral
marker
antibodi
use
diagnosi
acut
hbv
infect
current
test
definit
diagnos
acut
hepat
c
antihcv
hcv
rna
present
acut
chronic
hcv
infect
anti
initi
evalu
patient
sign
symptom
jaundic
fever
right
upper
quadrant
abdomin
pain
measur
aminotransferas
mark
increas
ul
either
enzym
usual
attribut
ischem
toxic
liver
injuri
histori
neg
either
diagnost
workup
continu
person
smaller
increas
viral
serolog
princip
test
evalu
acut
hepat
injuri
although
fall
incid
viral
diseas
made
caus
proport
common
prescript
nonprescript
drug
caus
acut
injuri
detail
drug
histori
critic
particularli
increas
alp
coexist
increas
alp
obstruct
virus
ebv
cmv
must
consid
well
alk
alkalin
phosphatas
nl
normal
hcv
detect
secondgener
enzym
immunoassay
acut
hcv
case
time
initi
increas
enzym
activ
wherea
hcv
rna
posit
essenti
case
although
intermitt
present
time
clinic
present
case
detect
antihcv
pattern
would
support
diagnosi
acut
hepat
c
neg
antihcv
posit
hcv
rna
hcv
rna
test
antihcv
result
convert
neg
posit
within
short
period
use
antibodi
hepat
viru
antihdv
detect
delta
hdv
infect
limit
patient
posit
hbsag
particularli
accompani
sever
acut
hepat
high
risk
factor
eg
intraven
drug
abus
hemophilia
biphas
pattern
ill
patient
chronic
hepat
b
becom
superinfect
hdv
clinic
pictur
resembl
sever
acut
hepat
injuri
hepat
failur
may
evolv
initi
evalu
acut
hepat
injuri
includ
detail
drug
histori
viral
marker
igm
antihav
igm
antihbc
hbsag
antihcv
iib
ischem
toxic
hepat
injuri
ast
alt
valu
higher
normal
rare
viral
hepat
common
toxin
ingest
especi
acetaminophen
ischem
hepat
injuri
acetaminopheninduc
hepat
injuri
peak
ast
ul
case
valu
virtual
never
seen
acut
viral
hepat
toxic
ischem
hepat
injuri
caus
case
acut
hepat
injuri
ast
activ
ul
ischem
acetaminophen
hepat
injuri
ast
alt
activ
typic
peak
earli
often
first
h
admiss
ast
activ
initi
higher
alt
peak
activ
fall
rapidli
ast
may
fall
first
h
declin
rapidli
alt
shorter
halflif
ast
activ
reach
near
normal
valu
averag
day
injuri
pt
refer
limit
case
fall
rapidli
peak
ast
reach
bilirubin
moll
mgdl
case
toxic
ischem
injuri
lactat
dehydrogenas
ec
activ
often
higher
ast
present
toxic
ischem
hepat
injuri
wherea
increas
initi
determin
case
viral
hepat
averag
valu
slightli
upper
refer
limit
rare
cocain
may
caus
hepat
injuri
usual
patient
coexist
hypotens
caus
rare
wilson
diseas
autoimmun
hepat
aih
discuss
detail
chronic
hepat
injuri
present
acut
hepat
injuri
monitor
aminotransferas
aminotransferas
activ
tend
increas
peak
near
onset
jaundic
viral
hepat
fall
gradual
point
onward
activ
tend
fall
slowli
viral
hepat
alcohol
hepat
ast
alt
decreas
averag
per
day
respect
remain
increas
day
respect
hepat
secondari
increas
enzym
occur
case
activ
return
baselin
associ
circul
hav
rna
viral
particl
stool
indic
potenti
transmiss
infect
discuss
ast
alt
fall
rapidli
reach
peak
activ
ischem
toxic
hepat
injuri
form
hepat
injuri
decreas
activ
occur
recoveri
massiv
necrosi
make
enzym
activ
poor
indic
recoveri
aminotransferas
shown
consist
pattern
decreas
need
check
patient
clinic
recov
return
aminotransferas
normal
reliabl
sign
recoveri
hepat
b
c
patient
chronic
hcv
infect
normal
alt
initi
visit
seroconvers
develop
increas
alt
subsequ
followup
hepat
b
ast
alt
may
return
normal
despit
persist
infect
bilirubin
bilirubin
peak
later
aminotransferas
often
week
gradual
decreas
peak
bilirubin
moll
mgdl
unusu
viral
hepat
patient
viral
hepat
peak
valu
moll
mgdl
peak
valu
moll
mgdl
higher
bilirubin
common
hbv
infect
total
bilirubin
declin
proport
increas
often
reach
total
bilirubin
adult
viral
hepat
bilirubin
remain
increas
day
peak
concentr
reach
clear
quickli
children
jaundic
remain
longer
week
adult
hbv
case
form
viral
hepat
prolong
increas
conjug
bilirubin
occasion
occur
viral
hepat
particularli
hav
signifi
poor
prognosi
synthet
function
remain
intact
significantli
increas
bilirubin
uncommon
toxic
ischem
hepat
injuri
serum
bilirubin
begun
decreas
reason
measur
unless
jaundic
worsen
clinic
coagul
test
increas
pt
common
find
ischem
toxic
hepat
injuri
often
result
refer
limit
rapidli
return
normal
data
extent
increas
affect
prognosi
ischem
hepat
injuri
increas
pt
refer
limit
viral
alcohol
hepat
marker
sever
diseas
recommend
pt
refer
limit
bilirubin
moll
mgdl
develop
encephalopathi
identifi
highrisk
patient
requir
close
monitor
consider
referr
gastroenterologist
hepatologist
iib
patient
acut
hepat
b
repeat
hbsag
measur
perform
within
month
neg
test
antihbv
surfac
antigen
antibodi
antihb
posit
addit
followup
need
iie
patient
acut
hepat
c
alt
measur
period
next
year
assur
continu
normal
result
iib
chronic
hepat
injuri
rel
common
disord
minim
symptom
longterm
risk
signific
morbid
mortal
defin
patholog
ongo
hepat
necrosi
inflamm
liver
often
accompani
fibrosi
chronic
hepat
injuri
may
progress
cirrhosi
case
chronic
hcv
predispos
hcc
commonli
result
chronic
viral
infect
unit
state
alon
estim
million
peopl
chronic
infect
hcv
also
million
chronic
carrier
hbv
unit
state
although
preval
rate
hcv
infect
gener
part
world
preval
rate
hbv
vari
markedli
mani
area
hbv
endem
infect
preval
endem
hbv
children
declin
mani
part
world
use
hbv
vaccin
clinic
find
laboratori
investig
often
adequ
establish
like
diagnosi
predict
valu
alcohol
hepat
chronic
viral
hepat
avail
hcv
test
compar
biopsi
recommend
absenc
liver
biopsi
show
chronic
hepat
one
follow
clinic
definit
use
diagnos
chronic
hepat
persist
increas
alt
month
episod
acut
hepat
increas
alt
without
anoth
explan
one
occas
period
month
shorter
time
may
appropri
patient
risk
factor
chronic
viral
hepat
genet
caus
hepat
injuri
autoimmun
liver
injuri
presenc
clinic
sign
symptom
liver
diseas
iib
although
definit
chronic
hepat
injuri
increas
alt
wide
accept
patient
chronic
hepat
c
persist
normal
alt
likelihood
continu
normal
alt
decreas
increas
number
measur
even
three
normal
alt
valu
patient
chronic
hcv
viremia
subsequ
develop
persist
increas
alt
alt
often
fluctuat
normal
abnorm
particularli
chronic
hepat
c
patient
multipl
alt
measur
least
occasion
normal
alt
valu
dr
dufour
unpublish
observ
major
patient
persist
normal
alt
histolog
evid
chronic
hepat
biopsi
gener
milder
inflamm
less
fibrosi
lower
rate
progress
cirrhosi
hcv
patient
increas
alt
center
diseas
control
prevent
guidelin
recommend
treatment
patient
hcv
persist
normal
alt
although
longterm
studi
need
appear
clinic
definit
propos
miss
signific
group
patient
requir
benefit
treatment
alway
possibl
distinguish
acut
chronic
hepat
injuri
patient
chronic
hepat
c
common
form
chronic
hepat
injuri
alt
valu
one
four
time
upper
refer
limit
maximum
alt
less
seven
time
upper
refer
limit
valu
lower
typic
seen
acut
hepat
case
howev
peak
alt
may
time
upper
refer
limit
often
associ
jaundic
pattern
similar
seen
acut
hepat
injuri
dr
dufour
unpublish
observ
case
often
necessari
addit
test
rule
anoth
caus
acut
hepat
injuri
screen
gener
screen
popul
chronic
hepat
injuri
costeffect
limit
highrisk
individu
includ
famili
histori
genet
diseas
known
affect
liver
discuss
risk
factor
chronic
viral
infect
tabl
alt
consist
higher
ast
caus
chronic
hepat
injuri
except
alcohol
ast
normal
substanti
number
case
alt
may
normal
patient
cirrhosi
wherea
ast
remain
increas
total
direct
bilirubin
alp
normal
essenti
patient
use
screen
increas
alt
found
routin
test
confirm
repeat
test
evalu
minor
individu
one
increas
alt
valu
found
liver
diseas
patient
slightli
increas
alt
one
two
time
upper
refer
limit
like
transient
increas
attribut
diseas
approxim
patient
chronic
hepat
injuri
attribut
hcv
peak
alt
activ
less
two
time
upper
refer
limit
patient
risk
factor
chronic
hbv
hcv
infect
tabl
alt
identifi
infect
individu
hbsag
antihcv
measur
screen
chronic
infect
chronic
carrier
hbv
typic
normal
alt
patient
chronic
hcv
infect
persist
intermitt
normal
alt
howev
likelihood
normal
valu
decreas
frequenc
test
individu
antihcv
detect
viremia
person
posit
antihcv
qualit
hcv
rna
perform
identifi
persist
infect
hcv
rna
may
transient
present
earli
stage
infect
patient
persist
increas
alt
posit
antihcv
neg
hcv
rna
test
repeat
screen
chronic
hepat
recommend
asymptomat
highrisk
individu
iib
iie
alt
costeffect
screen
test
metabol
druginduc
liver
injuri
ast
also
measur
histori
alcohol
abus
iib
iie
clinic
histori
suggest
alcohol
abus
andor
ast
activ
greater
alt
especi
twofold
higher
alt
activ
like
diagnosi
alcohol
hepat
virtual
form
chronic
hepat
injuri
caus
ast
higher
alt
unless
cirrhosi
develop
although
major
case
chronic
hepat
injuri
caus
virus
drug
ethanol
sever
disord
may
produc
chronic
hepat
injuri
addit
test
need
initi
evalu
consist
hepat
b
c
alcohol
hepat
prescript
drug
may
caus
persist
increas
alt
commonli
drug
sulfonamid
cholesterollow
agent
isoniazid
one
studi
area
low
preval
viral
hepat
histori
prescript
drug
use
common
chronic
hepat
injuri
recogniz
etiolog
despit
extens
laboratori
test
patient
increas
alt
neg
viral
marker
neg
histori
drug
alcohol
ingest
workup
includ
less
common
caus
chronic
hepat
injuri
tabl
initi
evalu
includ
detail
drug
histori
along
measur
hbsag
antihcv
antihcv
posit
chronic
infect
con
workup
patient
without
obviou
caus
chronic
hepat
injuri
nonalcohol
steatohepat
nash
occurr
chronic
liver
diseas
histolog
resembl
alcohol
hepat
patient
without
alcohol
abus
term
nash
common
caus
chronic
hepat
injuri
virus
alcohol
common
caus
cryptogen
cirrhosi
although
nash
occur
commonli
middleag
women
obes
andor
diabet
also
occur
men
patient
without
risk
factor
patient
nash
commonli
abnorm
lipid
profil
although
normal
result
rule
diseas
differ
alcohol
hepat
alt
activ
higher
ast
except
patient
cirrhosi
weight
loss
may
caus
signific
improv
enzym
result
one
studi
reduct
weight
produc
decreas
alt
activ
recommend
biopsi
necessari
establish
diagnosi
nash
iib
hemochromatosi
autosom
recess
trait
hemochromatosi
common
inherit
genet
defect
person
northern
european
ancestri
unit
state
vast
major
case
produc
one
two
point
mutat
hfe
gene
chromosom
major
affect
individu
homozyg
mutat
wherea
minor
compound
heterozygos
mutat
mutat
screen
involv
detect
increas
transferrin
satur
satur
serum
iron
ironbind
capac
low
unsatur
ironbind
capac
transferrin
satur
cutoff
unsatur
ironbind
capac
cutoff
moll
g
dl
sensit
homozygos
mutat
fast
specimen
use
specif
recent
consensu
confer
recommend
definit
diagnosi
made
genet
analysi
although
sever
recent
public
shown
feasibl
hemochromatosi
screen
use
transferrin
satur
organ
research
current
recommend
screen
unresolv
issu
regard
abil
convinc
young
adult
test
specif
reproduc
screen
test
question
natur
histori
untreat
diseas
screen
advoc
colleg
american
pathologist
estim
save
per
blood
donor
screen
initi
evalu
hemochromatosi
fast
serum
transferrin
satur
unsatur
ironbind
capac
iib
transferrin
satur
unsatur
ironbind
capac
moll
gdl
follow
analysi
hfe
gene
mutat
iib
screen
popul
may
benefici
current
recommend
pend
clarif
screen
benefit
iib
iie
wilson
diseas
autosom
recess
disord
wilson
diseas
occur
individu
europ
north
america
caus
mutat
gene
chromosom
code
atpas
need
copper
transport
wilson
diseas
may
present
liver
diseas
neurolog
problem
psychiatr
symptom
almost
alway
age
patient
present
liver
diseas
neurolog
manifest
common
diagnost
find
low
plasma
ceruloplasmin
low
concentr
also
occur
malnutrit
protein
loss
advanc
liver
diseas
fals
normal
valu
occur
pregnanc
estrogen
administr
acut
inflamm
refer
report
low
ceruloplasmin
homozygot
heterozygot
one
studi
found
normal
ceruloplasmin
patient
chronic
liver
diseas
attribut
wilson
diseas
confirm
genet
studi
patient
wilson
diseas
without
overt
liver
involv
expect
find
wilson
diseas
includ
increas
serum
free
copper
decreas
total
serum
copper
increas
urin
copper
excret
increas
liver
copper
content
test
may
also
provid
mislead
result
patient
wilson
diseas
multipl
test
frequent
need
establish
diagnosi
test
wilson
diseas
ceruloplasmin
indic
patient
age
chronic
hepat
injuri
fatti
liver
neg
workup
viral
hepat
druginduc
liver
injuri
hemochromatosi
iib
screen
wilson
diseas
patient
chronic
hepat
injuri
indic
iib
iie
genet
marker
test
may
use
equivoc
case
test
must
abl
detect
multipl
mutat
wilson
diseas
gene
iiib
aih
aih
respons
chronic
hepat
attribut
virus
alcohol
sever
variant
aih
describ
type
found
primarili
young
middleag
women
common
form
associ
high
titer
ana
andor
antismooth
muscl
antibodi
asma
type
found
primarili
children
common
western
europ
rare
unit
state
associ
antibodi
liverkidney
microsom
antigen
rare
posit
ana
asma
mani
patient
type
also
hcv
infect
type
found
primarili
young
women
associ
system
autoimmun
diseas
mani
case
affect
individu
lack
ana
asma
antiliverkidney
microsom
antibodi
posit
antibodi
solubl
liver
antigen
standard
diagnost
criteria
score
system
defin
intern
panel
classic
featur
common
type
includ
increas
aminotransferas
minim
increas
alp
polyclon
hypergammaglobulinemia
least
time
upper
refer
limit
evid
viral
infect
risk
factor
viral
infect
exposur
drug
alcohol
posit
ana
asma
least
approxim
patient
chronic
hcv
infect
posit
ana
asma
usual
low
titer
falseposit
antihcv
result
report
patient
aih
secondgener
test
use
thirdgener
assay
use
antihcv
typic
disappear
success
treatment
equivoc
case
hcv
rna
recombin
immunoblot
assay
use
establish
diagnosi
aih
suspect
patient
chronic
hepat
injuri
increas
immunoglobulin
absenc
viral
marker
risk
factor
viral
hepat
iiib
diagnosi
type
aih
clinic
support
posit
either
ana
asma
high
titer
iiib
primari
biliari
cirrhosi
pbc
primari
scleros
cholang
psc
autoimmun
diseas
caus
destruct
bile
duct
although
pbc
psc
characterist
caus
increas
alp
ec
patient
diseas
may
increas
ast
alt
consid
chronic
hepat
pbc
associ
destruct
intrahepat
bile
duct
often
associ
autoimmun
disord
particularli
sjogren
syndrom
case
autoimmun
marker
antimitochondri
antibodi
ama
found
almost
patient
pbc
although
diseas
may
associ
posit
ama
pbc
antibodi
direct
pyruv
dehydrogenas
complex
socal
type
ama
particularli
dihydrolipoamid
acetyltransferas
protein
approxim
patient
featur
pbc
aih
pbc
often
detect
asymptomat
individu
find
increas
alp
ast
alt
increas
approxim
onehalf
case
although
valu
two
time
refer
limit
psc
associ
damag
intraand
extrahepat
bile
duct
case
associ
inflammatori
bowel
diseas
crohn
diseas
ulcer
coliti
perinuclear
antineutrophil
cytoplasm
antibodi
found
approxim
twothird
case
psc
antibodi
commonli
direct
bactericidalpermeabilityincreas
protein
cathepsin
g
andor
lactoferrin
appear
prognost
signific
differ
antibodi
specif
although
patient
cirrhosi
commonli
antibodi
multipl
antigen
antigen
lactoferrin
asma
ana
also
present
case
pbc
psc
suspect
patient
chronic
cholestasi
iiib
diagnosi
clinic
support
posit
ama
pbc
antineutrophil
cytoplasm
antibodi
psc
high
titer
iiib
defici
import
proteas
inhibitor
congenit
defici
occur
person
european
ancestri
gene
locat
chromosom
defici
usual
attribut
singl
amino
acid
substitut
alter
carbohydr
bind
impair
releas
hepatocyt
import
defici
involv
homozygos
z
variant
term
pi
proteas
inhibitor
zz
defici
associ
emphysema
neonat
hepat
chronic
hepat
injuri
cirrhosi
hcc
also
report
almost
pi
zz
neonat
evid
liver
injuri
birth
usual
resolv
age
year
adult
pi
zposit
individu
either
homozygot
heterozygot
develop
cirrhosi
develop
hcc
also
excess
pi
z
heterozygot
among
patient
refer
liver
transplant
particularli
among
patient
cryptogen
cirrhosi
patient
pi
z
posit
evid
howev
defici
heterozygos
pi
z
phenotyp
may
directli
caus
liver
diseas
increas
suscept
liver
damag
agent
especi
virus
two
control
studi
found
frequenc
pi
z
either
homozyg
heterozyg
patient
liver
diseas
control
studi
patient
pi
z
chronic
liver
diseas
also
posit
hcv
antibodi
hbv
marker
liver
diseas
risk
factor
acut
phase
reactant
quantit
concentr
may
fals
normal
infect
inflamm
fals
low
concentr
may
occur
malnutrit
proteinlos
state
end
stage
liver
diseas
one
studi
quantit
concentr
normal
heterozyg
pi
z
patient
liver
diseas
test
defici
use
phenotyp
analysi
rather
quantit
plasma
concentr
recommend
test
defici
may
benefit
patient
chronic
hepat
injuri
appar
caus
although
role
defici
liver
diseas
adult
clearli
defin
iib
test
especi
import
neonat
evid
hepat
injuri
iib
test
variant
perform
determin
phenotyp
iib
screen
patient
chronic
hepat
injuri
defici
recommend
iiib
iiie
two
virus
suggest
possibl
involv
pathogenesi
chronic
hepat
hepat
g
hgv
tt
viru
ttv
virus
transmit
transfus
chronic
viremia
present
date
evid
suggest
infect
virus
common
clear
indic
play
role
liver
injuri
hgv
relat
gb
viru
type
c
member
flaviviru
famili
hcv
hgv
first
isol
patient
follow
transfus
although
show
evid
liver
injuri
hgv
also
frequent
found
chronic
hepat
appear
common
caus
cryptogen
chronic
liver
diseas
may
hgv
rna
rare
found
liver
chronic
virem
patient
ttv
first
identifi
patient
posttransfus
hepat
ttv
dna
found
blood
donor
unit
state
presenc
ttv
dna
common
person
acut
nona
hepat
caus
acut
hepat
control
patient
recommend
test
hgv
ttv
research
set
recommend
iiie
although
alt
clinic
use
laboratori
test
monitor
liver
injuri
often
consider
fluctuat
enzym
activ
time
particularli
chronic
hcv
infect
import
measur
alt
repeatedli
chronic
hcv
conclud
alt
normal
chronic
infect
individu
alt
valu
fluctuat
normal
abnorm
normal
alt
first
two
visit
normal
alt
first
three
visit
subsequ
develop
increas
alt
patient
chronic
hbv
infect
without
increas
alt
chronic
carrier
develop
increas
alt
followup
alt
therefor
measur
period
even
initi
normal
chronic
hbv
hcv
clearanc
viral
marker
reliabl
method
detect
resolut
infect
untreat
hepat
b
small
percentag
patient
spontan
clear
viral
antigen
longterm
studi
loss
hbeag
occur
onethird
onehalf
patient
lose
hbeag
subsequ
clear
hbsag
year
followup
hbeag
recheck
period
initi
posit
hbeag
neg
antihbv
e
antigen
antibodi
antihb
posit
may
indic
either
begin
viral
clearanc
bodi
integr
hbv
dna
host
dna
loss
abil
form
replic
viru
hbsag
antihb
measur
period
look
viral
clearanc
hbsag
remain
posit
integr
hbv
dna
treatment
hbv
likelihood
viral
clearanc
relat
baselin
alt
activ
patient
increas
alt
like
respond
initi
normal
alt
activ
success
treatment
associ
loss
hbv
dna
hbsag
hbeag
although
evid
quantit
hbeag
correl
well
hbv
dna
quantit
hbeag
assay
commerci
avail
hbeag
may
disappear
even
patient
show
respons
therapi
moreov
increas
frequenc
precor
mutant
produc
hbeag
particularli
endem
area
asia
mediterranean
region
patient
infect
mutant
antihb
continu
circul
hbv
dna
infect
normal
strain
hbv
dna
remain
detect
longer
hbsag
recoveri
viral
dna
integr
host
genom
hbsag
still
produc
although
hbeag
hbv
dna
commonli
neg
plasma
lamivudin
treatment
howev
product
viral
nucleic
acid
revers
transcriptas
inhibit
although
viral
dna
concentr
hepatocyt
chang
reason
use
hbv
dna
hbeag
hbsag
may
use
monitor
patient
chronic
hbv
singl
test
provid
unequivoc
evid
viral
clearanc
studi
shown
hcv
rna
fluctuat
time
rare
vari
log
case
variat
log
patient
test
repeatedli
sever
year
hcv
rna
increas
clinic
chemistri
averag
logyear
time
without
treatment
seri
howev
differ
seen
patient
increas
alt
hcv
rna
measur
monthli
approxim
onethird
chronic
infect
patient
hcv
rna
fluctuat
mean
copiesml
undetect
current
antivir
treatment
recommend
patient
chronic
hcv
infect
increas
alt
mild
inflammatori
chang
biopsi
effect
therapi
current
avail
combin
ribavirin
interferon
laboratori
test
found
help
predict
respons
vari
length
therapi
detect
respond
treatment
therapi
probabl
discontinu
treat
combin
therapi
viral
load
genotyp
found
identifi
patient
may
respond
rather
week
therapi
combin
analysi
two
studi
five
factor
found
use
predict
respons
tabl
person
genotyp
along
three
four
favor
risk
factor
treat
effect
week
therapi
patient
better
week
therapi
best
indic
viral
clearanc
persist
absenc
hcv
rna
determin
qualit
hcv
rna
assay
absenc
hcv
rna
month
complet
treatment
associ
likelihood
recurr
hcv
viremia
decreas
viral
load
absenc
clearanc
reliabl
evid
treatment
success
howev
failur
hcv
rna
declin
copiesml
week
therapi
associ
likelihood
persist
hcv
rna
end
treatment
approach
monitor
treatment
patient
hcv
combin
therapi
outlin
fig
patient
take
ribavirin
current
treatment
option
patient
interferon
monotherapi
form
treatment
failur
hcv
rna
fall
undetect
concentr
failur
alt
return
normal
week
initi
therapi
associ
likelihood
treatment
failur
consid
reason
discontinu
therapi
optim
frequenc
laboratori
test
patient
chronic
hepat
c
determin
european
associ
studi
liver
consensu
confer
hepat
c
recommend
complet
blood
count
liver
enzym
perform
everi
month
untreat
patient
major
complic
treatment
interferon
depress
thrombocytopenia
hypothyroid
wherea
hemolyt
anemia
major
complic
ribavirin
therapi
european
associ
studi
liver
recommend
complet
blood
count
weekli
first
week
treatment
regular
determin
first
week
also
recommend
measur
thyroidstimul
hormon
everi
month
therapi
viral
hepat
viral
marker
reliabl
marker
resolut
hepat
iib
hcv
rna
quantif
genotyp
import
determin
durat
combin
therapi
reduc
expens
test
feasibl
specimen
obtain
treatment
store
pend
result
treatment
possibl
test
perform
treatment
begun
iib
iie
patient
hcv
treat
interferon
ribavirin
qualit
hcv
rna
measur
week
treatment
determin
potenti
respond
genotyp
quantit
hcv
rna
perform
specimen
frozen
analysi
treatment
neg
hcv
rna
favor
risk
factor
test
perform
ib
ie
patient
hcv
treat
interferon
monotherapi
qualit
hcv
rna
alt
measur
week
treatment
determin
nonrespond
iib
follow
treatment
neg
hcv
rna
week
sensit
hcv
rna
measur
current
qualit
assay
perform
month
end
treatment
document
sustain
virolog
remiss
iib
untreat
patient
hbv
hbeag
monitor
period
hbeag
neg
antihb
posit
hbsag
monitor
period
determin
viral
clearanc
antivir
therapi
hbv
dna
also
use
document
viral
clearanc
iib
treat
patient
complet
blood
count
platelet
measur
everi
week
first
week
monthli
thereaft
thyroidstimul
hormon
measur
everi
month
sooner
symptom
thyroid
dysfunct
develop
measur
alt
perform
least
monthli
iiib
alt
best
marker
inflammatori
activ
avail
limit
util
predict
degre
inflamm
use
estim
sever
fibrosi
iib
chronic
hepat
classifi
histolog
base
activ
inflamm
degre
fibrosi
extent
fibrosi
relat
likelihood
develop
cirrhosi
enzym
activ
reflect
sever
fibrosi
major
factor
prognosi
best
weak
correl
plasma
alt
activ
chronic
hcv
hcv
rna
concentr
histolog
activ
best
alt
explain
variat
histolog
activ
consider
overlap
valu
patient
mild
moder
sever
activ
relat
rate
progress
fibrosi
liver
fibrosi
associ
deposit
sever
protein
liver
among
protein
produc
part
fibrosi
collagen
laminin
elastin
fibronectin
metalloproteinas
inhibitor
enzym
produc
collagen
synthesi
lysyl
prolyl
hydroxylas
variou
proteoglycan
hyaluron
also
produc
process
fibrosi
numer
studi
plasma
concentr
proteoglycan
protein
fibrosi
precursor
shown
best
weak
correl
marker
concentr
extent
fibrosi
concentr
reflect
degre
fibrogenesi
time
sampl
consider
overlap
valu
vari
degre
fibrosi
simpl
marker
calcul
routin
monitor
test
ast
alt
ratio
sever
studi
shown
ratio
typic
patient
nonalcohol
hepat
progress
cirrhosi
ratio
often
increas
specif
ratio
cirrhosi
sensit
one
studi
ratio
increas
increas
fibrosi
score
appear
attribut
reduct
alt
product
damag
liver
routin
test
result
predict
likelihood
cirrhosi
thrombocytopenia
prolong
pt
index
use
two
variabl
ast
alt
ratio
sensit
specif
cirrhosi
albumin
commonli
measur
patient
suspect
progress
cirrhosi
although
sensit
marker
use
marker
sever
part
childpugh
classif
cirrho
present
combin
ribavirininterferon
recommend
patient
without
contraind
hcv
rna
measur
week
treatment
posit
treatment
discontinu
neg
durat
treatment
base
number
favor
risk
factor
present
see
tabl
four
factor
favor
genotyp
treatment
stop
case
treatment
continu
week
storag
avail
specimen
hcv
genotyp
viral
load
obtain
treatment
frozen
test
perform
test
perform
therapi
patient
toler
ribavirin
monotherapi
interferon
use
alt
qualit
hcv
rna
check
week
therapi
alt
remain
increas
hcv
rna
detect
treatment
discontinu
benefit
determin
quantit
hcv
rna
genotyp
interferon
monotherapi
use
clinic
chemistri
si
afp
like
increas
degre
hepat
fibrosi
increas
especi
cirrhosi
afp
gl
sensit
specif
posit
predict
valu
cirrhosi
biopsi
definit
marker
progress
chronic
hepat
cirrhosi
iib
laboratori
marker
fibrosi
use
except
research
studi
iiib
iiie
marker
hepat
function
may
indic
progress
cirrhosi
ast
alt
ratio
albumin
pt
platelet
count
measur
everi
month
patient
chronic
hepat
iiib
primari
liver
cancer
hcc
seriou
late
complic
chronic
hepat
injuri
particularli
cirrhosi
caus
hbv
hcv
hemochromatosi
infrequ
hcc
seen
patient
chronic
hcv
asymptomat
hbv
carrier
without
cirrhosi
fifth
common
malign
worldwid
particularli
common
eastern
asia
africa
incid
hcc
increas
unit
state
past
year
particularli
among
younger
patient
increas
part
world
well
risk
develop
hcc
cirrhosi
attribut
chronic
hbv
hcv
infect
per
year
studi
case
hcc
occur
patient
cirrhosi
howev
cirrhosi
recogn
clinic
hcc
diagnos
data
suggest
screen
program
institut
must
includ
patient
chronic
hepat
injuri
well
patient
diagnos
cirrhosi
one
studi
howev
hcc
develop
patient
sever
chronic
hepat
cirrhosi
patient
mild
moder
chronic
hepat
patient
normal
alt
gener
mild
inflamm
biopsi
reason
exclud
screen
person
without
cirrhosi
normal
alt
less
sever
hepat
biopsi
risk
factor
includ
male
gender
age
year
prognosi
patient
hcc
detect
develop
symptom
grim
patient
surviv
month
detect
small
tumor
offer
potenti
cur
resect
form
rational
consid
screen
current
practic
suggest
measur
afp
ultrasound
liver
everi
month
unfortun
afp
interpret
complic
intermitt
increas
afp
concentr
patient
chronic
hbv
hcv
often
alway
associ
transient
increas
alt
consensu
develop
workshop
recommend
screen
chronic
hbsag
carrier
least
prefer
twice
yearli
afp
wherea
patient
risk
factor
known
cirrhosi
famili
histori
afp
ultrasound
chronic
hepat
injuri
high
risk
hcc
present
patient
hemochromatosi
cirrhosi
caus
hbv
hcv
alcohol
abus
caus
chronic
hepat
injuri
cirrhosi
lower
risk
hcc
western
countri
predict
valu
afp
low
often
rang
sensit
afp
patient
cirrhosi
none
patient
hcc
afp
gl
time
diagnosi
afp
gl
howev
frequenc
hcc
patient
afp
gl
compar
higher
afp
anoth
studi
patient
cirrhosi
hcc
develop
patient
initi
afp
gl
higher
concentr
moreov
even
transient
increas
gl
significantli
higher
risk
hcc
whose
afp
consist
gl
decis
analysi
publish
report
screen
hcc
western
patient
compens
cirrhosi
conclud
patient
likelihood
surviv
year
screen
would
like
add
month
averag
life
expect
cost
per
year
life
gain
figur
compar
favor
colon
cancer
breast
cancer
screen
patient
lower
likelihood
surviv
screen
provid
minim
gain
life
expect
appear
indic
systemat
analysi
publish
studi
conclud
inadequ
data
determin
benefit
screen
hcc
among
patient
chronic
liver
diseas
screen
use
frequenc
test
everi
month
appear
optim
base
observ
doubl
time
hcc
report
averag
month
prothrombin
also
suggest
screen
test
concentr
increas
occasion
chronic
liver
diseas
less
overlap
valu
seen
hcc
afp
occasion
high
concentr
encount
metastat
carcinoma
liver
usual
minim
increas
although
prothrombin
appear
less
sensit
afp
specif
poor
correl
afp
prothrombin
tumor
detect
prothrombin
vitamin
k
defici
also
caus
substanti
increas
repeat
test
administr
vitamin
k
improv
specif
recent
sensit
immunoassay
shown
promis
detect
small
hcc
posit
case
compar
older
assay
assay
prothrombin
wide
avail
contrast
afp
assay
laboratori
test
includ
afp
variant
lectin
affin
chromatographi
alp
evalu
patient
make
definit
recommend
recent
studi
identifi
high
concentr
abnorm
form
patient
hcc
patient
liver
diseas
screen
hcc
question
benefit
western
popul
iib
iie
screen
confin
highrisk
patient
sever
chronic
hepat
cirrhosi
attribut
alcohol
hbv
hcv
hemochromatosi
candid
treatment
hcc
detect
iiib
iiie
screen
use
measur
afp
ultrasound
interv
frequent
everi
month
recommend
iib
current
data
support
use
test
iiib
